{'fraction_non_alphanumeric': 0.04988913525498891, 'fraction_numerical': 0.036585365853658534, 'mean_word_length': 4.825806451612904, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A trial of glucagon in the treatment of painful biliary tract disease

Seventy‐one patients with a clinical diagnosis of painful biliary tract disease have been entered into a double‐blind trial of glucagon. Twenty‐eight were excluded as gallstones were not proved: of the remainder, 21 patients received glucagon and 22 placebo. Glucagon‐treated patients were pain free 14·26 h(± 2·77 s.e.m.) after commencing treatment compared to 29·14 h(± 6·01 s.e.m.) for the placebo group (P < 0·05). Tenderness in the right hypochondrium showed a significant improvement when assessed at 12 h (P < 0·02) and 24 h (P < 0·1) for those given glucagon. A significant difference in blood glucose levels was seen between the two groups (P < 0·05). No serious side effects were observed. Glucagon relieves the pain and tenderness associated with painful biliary tract disease more effectively than conventional therapy.